Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 23

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 3
Chunk 23
---
 options. Of the options granted, 9,000 were granted with an exercise price of NIS 26.6 ($7.29), 3,600 were
granted with an exercise price of $6.6 per share, and 140,000 were granted with an exercise price of NIS 8.62 ($2.36) per share. The options
detailed above expire within ten years from the date of grant. During 2024, two executive officers, who serve as chief executive officers
in two of our subsidiaries, were granted options to purchase equity of such subsidiaries, which are not detailed above. The number of
options above, and their respective exercise prices, are presented on an as-adjusted basis, after giving effect to the Reverse Split.

The following table presents information regarding compensation
accrued in our financial statements for the year ended December 31, 2024 for our five most highly compensated executive officers, as required
under Israeli Securities Law 5728-1968 and the regulations promulgated thereunder.

                                                  (in thousands, US$)(1)                            
  Name and Position                          Salary and related benefits                            
  Ofer Haviv                                                         374      49        1      424  
  Amit Noam                                                          187      29      448      664  
  Dan Gelvan                                                         210      -       159      369  
  Elran Haber                                                        251      -        48      299  
  Yoash Zohar                                                        251      -       332      583  

  (1)      All amounts reported in the table are in terms of cost to the Company, as recorded in our financial statements.  

  (2)      Bonus amounts shown in this table reflect bonuses that were paid in 2024 relating to the office holders’ service in our Company                   
           in 2023, as approved by our Compensation and Nominating Committee and Board of Directors, and, to the extent required, also by our shareholders.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (3)      Consists of amounts recognized as non-cash expenses in our statement of profit or loss for the year ended December 31, 2024 in respect  

82

Compensation Policy

As required by the Companies Law, we have adopted a policy regarding
the terms of engagement of office holders, or a compensation policy. Under the Companies Law